S100B protein in the blood of children with autism spectrum disorders

Голубова, Т Ф; Цукурова, Л А; Korsunskaya, L.L.; Osipyan, R R; Власенко, С В; Савчук, Е А

doi:10.17116/jnevro201911912176

Cited by 4 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study by Tomova et al (5), higher plasma S100B levels were reported in children diagnosed with autism compared to non-autistic controls. Similar results have also been reported by Ayaydin et al (8) and by Golubova et al (9) with serum S100B levels in the ASD group being higher than those in the control group. It appears that there is inconsistency between the studies' results.…”

Section: Discussionsupporting

confidence: 90%

“…found higher plasma S100B values in severe ASD than in mild-to-moderate ASD based on CARS scores but also showed that S100B concentrations were no longer significantly different between children with severe ASD and those with less severe ASD after controlling for age, sex, and BMI. In the study conducted by Golubova et al(9), serum S100B levels were found higher in children with severe ASD. On the other hand, although Al-Ayadhi and Mostafa(7) revealed a positive correlation between CARS score and serum S100B levels in ASD patients it was not statistically significant.Shaker et al (…”

mentioning

confidence: 84%

“…Studies investigating the relation between S100B values and ASD in children revealed intriguing results. Elevated serum S100B levels in children with ASD have been reported by Al-Ayadhi and Mostafa (7), Ayaydın et al (8), and Golubova et al (9), whereas elevated plasma S100B levels in children with ASD have been shown by Guloksuz et al (10) and Tomova et al (5). On the other hand, Esnafoglu et al (2) reported that there was no difference in serum S100B between children with ASD and a healthy control group.…”

Section: Introductionmentioning

confidence: 90%

See 2 more Smart Citations

Evaluation of Serum S100B Levels in Male Children Younger than 6 Years Old with Autism Spectrum Disorder: A Psychiatric and Biochemical Perspective

Eraslan

Durukan

Bodur

et al. 2021

Düzce Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

Aim: Autism spectrum disorder is a neurodevelopmental disorder. The S100 calcium binding protein B (S100B) is among the markers of astrocyte activation as well as brain damage. Herein, it was aimed to evaluate S100B levels to determine whether there is a relation with the severity of autism spectrum disorder and establish possible causes of different results among the studies in the literature from a psychiatric and biochemical perspective. Material and Methods: Twenty-five male children with autism spectrum disorder were included as the study group along with twenty-seven male children as the control group. The childhood autism rating scale and the autism behavior checklist were applied. Serum S100B protein levels were measured by enzyme-linked immunosorbent assay (ELISA). Results:The mean serum S100B level was 1008.61±171.34 pg/mL in the study group and 1060.14±182.83 pg/mL in the control group, and no statistically significant difference was found between the groups (p=0.300). Based on the childhood autism rating scale scores, 60% (n=15) of the children with autism spectrum disorder had severe autism, whereas 40% (n=10) had mild-to-moderate autism. There was no significant difference in terms of the serum S100B levels between the groups of autism spectrum disorder severity (p=0.935) or according to the autistic regression status (p=0.667). Conclusion: For S100B to be accepted as a reliable biomarker for autism spectrum disorder, more studies considering some factors with larger samples should be performed. Moreover, to understand the effect of biochemical methodology on the results, further studies are suggested on this subject.

show abstract

Section: Discussionsupporting

confidence: 90%

mentioning

confidence: 84%

Section: Introductionmentioning

confidence: 90%

See 1 more Smart Citation

Evaluation of Serum S100B Levels in Male Children Younger than 6 Years Old with Autism Spectrum Disorder: A Psychiatric and Biochemical Perspective

Eraslan

Durukan

Bodur

et al. 2021

Düzce Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

show abstract

A large-scale genetic correlation scan identified the plasma proteins associated with brain function related traits

Liang

Cheng

et al. 2020

Brain Research Bulletin

View full text Add to dashboard Cite

Pathogenetic aspects of the development of autism spectrum disorders

Stupak,

Keshishyan,

Garina

2024

Ross. vestn. perinatol. pediatr.

View full text Add to dashboard Cite

There is currently an increase in the number of patients diagnosed with autism spectrum disorders due to the broad interpretation of the criteria for this diagnosis and an actual increase in the number of children with impaired communication and behavioral functions. There are different in their cause, but clinically similar conditions that are attributed to this group. However, the difference in pathogenetic causes may require different approaches to treatment — selection of pharmacological and pedagogical methods of therapy and rehabilitation of these clinical conditions.In this article, we plan to discuss possible causes of idiopathic (primary) autism spectrum disorders complex, i.e., when there is no indication that the child has conditions or diseases that may lead to the autism spectrum disorders symptom complex (syndromal autism): perinatal disorders, microanomalies of brain structures, sluggish infections (e.g., CMV infection with smoldering encephalitis), and autoimmune brain damage, chromosomal and genetic diseases with an identified gene with pathogenic significance. When discussing autism spectrum disorders or autism without the above conditions, a genetic model is also assumed, but with the inclusion of a large number of candidate genes, without specifying a clear contribution of each gene to pathogenicity.Numerous studies show that the mechanism of these disorders in autochthonous disease is related to the disruption of synaptic transmission, changes in the ontogenesis of the nervous system in the context of combinations of genetic disorders, as well as the resulting mechanisms of autoinflammatory changes in the structures of the central nervous system. Changes in the permeability of the hematoencephalic barrier, inflammation and disturbance of the glymphatic system are also considered as probable mechanisms of autism spectrum disorders pathophysiology. As a result of impaired synaptogenesis, differentiation and neurogenesis, the resulting excitotoxicity of neurotransmitters and their metabolites, reliably contribute to the formation of the maintenance of this process.

show abstract

S100B protein in the blood of children with autism spectrum disorders

Cited by 4 publications

References 16 publications

Evaluation of Serum S100B Levels in Male Children Younger than 6 Years Old with Autism Spectrum Disorder: A Psychiatric and Biochemical Perspective

Evaluation of Serum S100B Levels in Male Children Younger than 6 Years Old with Autism Spectrum Disorder: A Psychiatric and Biochemical Perspective

A large-scale genetic correlation scan identified the plasma proteins associated with brain function related traits

Pathogenetic aspects of the development of autism spectrum disorders

Contact Info

Product

Resources

About